Even though injectable vials of insulin have been around for nearly a century, and synthetic insulin for almost 40 years, there is no generic form of the vital diabetes medication. In recent years, the price of insulin has risen sharply, leaving healthcare providers with concerns about patients who can’t afford insulin skipping doses and risking lost limbs and eyesight. Pharma giant Eli Lilly — maker of popular insulin brands Humalog, Humulin, and Basaglar — is now proposing a solution that it believes could make the medication more affordable — but only for some people. [More]
